Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892691 · ClinicalTrials.gov registry record · NA
Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions
A NA study of Cancer and Pleural Effusion, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- NA
- Development phase
- 98
- Enrollment target
- 2
- Study locations
NCT06892691: Recruiting NA study of Cancer and Pleural Effusion, sponsored by Icahn School of Medicine at Mount Sinai.
NCT06892691 is a NA study of Cancer and Pleural Effusion that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 98 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06892691, a NA study of Cancer and Pleural Effusion, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- NA
- Development phase
- 98 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.
Primary Outcome
Proportion of biopsies adequate for definitive diagnosis
Conditions Studied
Interventions
- PROCEDURE Pleuroscopy first
- PROCEDURE Thoracentesis first
Study Locations (2)
New York
- Mount Sinai West - New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2025-03-24 |
| Est. Completion | 2026-09-17 |
| Phase | NA |
What NCT06892691 shows while recruiting
NCT06892691 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pleuroscopy first is the first listed.
NCT06892691 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06892691 about?
NCT06892691 is a clinical study titled "Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions". This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.
What is the current status of trial NCT06892691?
This trial is currently recruiting. It is a NA study. The enrollment target is 98 participants. The study started on 2025-03-24. Estimated completion is 2026-09-17.
What conditions does trial NCT06892691 study?
This clinical trial studies the following conditions: Cancer, Pleural Effusion.
What interventions are being tested in trial NCT06892691?
The interventions under investigation include: Pleuroscopy first (PROCEDURE), Thoracentesis first (PROCEDURE).
Who is sponsoring clinical trial NCT06892691?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06892691 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06892691's enrollment target sits among peer trials
98 330th of 615 higher than 286 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI